Trigeminal neuralgia
Conditions
Interventions
Control group:Conventional medication treatment (Oxcarbazepine, oral 300-600mg/time, 2 times/day)+head mounted device without effective stimulation
tTIS group:Conventional drug therapy (Oxcarbazepine, oral 300-600mg/time, 2 times/day)+tTIS treatment
Sponsors
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Those diagnosed with trigeminal neuralgia and for whom conventional drug treatment is ineffective or intolerable; 2. Age between 40 and 75 years old; 3. ASA I-II; 4. Visual Analogue Scale (VAS) score >= 3 points; 5. The patient or the patient's family has signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Comorbid with other chronic pain disorders; 2. Complicated with severe liver and kidney function impairments; 3. Exhibiting obvious mental disorders; 4. Presenting severe anxiety and depression; 5. Accompanied by epilepsy; 6. Arrhythmia; 7. Individuals who have metal implants in their brain after surgery; 8. Pregnant or postpartum women; 9. History of drug abuse; 10. Participating in other clinical studies related to pain treatment; 11. for tTIS treatment; 12. Those who refuse to cooperate for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain Visual Analogue Scale (VAS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Brief pain inventory, BPI;Self-Rating Depression Scale, SDS;Self-Rating Anxiety Scale, SAS;Pittsburgh sleep quality index, PSQI;Five-dimensional health scale; | — |
Countries
China
Contacts
Public ContactXuebi Tian
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed